The development of human hematopoietic prostaglandin D2 synthase inhibitors in allergic asthma and related disorders [ 2012 - 2014 ]

Research Grant

Researchers: A/Pr Mark Smythe (Principal investigator) ,  A/Pr Simon Phipps ,  Dr Jack Flanagan

Brief description Prostaglandin D2 (PGD2) is a key mediator of asthma and allergic rhinitis. We have developed drug-like compounds that block the synthesis of PGD2 by inhibiting the hematopoietic prostaglandin D2 synthase (HPGD2S) enzyme. This project aims to evaluate the potential of these compounds to treat asthma and to further optimize the drug-like characteristics of our lead molecules.

Funding Amount $AUD 428,071.63

Funding Scheme Development Grants

Notes Development Grant